Unfortunately, this has hardly improved since 2014: in our study transferrin saturation was determined in only 19.5% of patients overall and in 16.9% and 15.4% of patients with lung cancer and malignant lymphoma, respectively. This evidence concerns the gene TF and lung carcinoma.